Fig. 2From: CGRP-targeted medication in chronic migraine - systematic reviewChange in monthly headache days after 3 months of treatment with anti-CGRP mAb. Legend: Epti: eptinezumab; Erenu: erenumab; Frema: fremanezumab; Galca: galcanezumabBack to article page